Clinical Study
Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
Table 1
Young-elderly patients’ features.
| | | Overall | KRAS wild-type | KRAS mutant | | | Total no. (%) | Total no. (%) | Total no. (%) |
| | No. of patients | 28 | 13 (50) | 13 (50) | | Sex | | | | | Male/female | 14/14 | 6/7 | 8/5 | | Age, years | | | | | Median | 67 | 67 | 68 | | Range | 65–73 | 65–73 | 66–73 | | WHO performance status | | | | | 0 | 25 (89) | 12 (92) | 11 (85) | | 1-2 | 3 (11) | 1 (8) | 2 (15) | | CIRS stage | | | | | Primary | 2 (7) | — | 2 (15) | | Intermediate | 26 (93) | 13 (100) | 11 (85) | | Metastatic disease | | | | | Metachronous | 10 (36) | 5 (38) | 5 (38) | | Synchronous | 18 (64) | 8 (62) | 8 (62) | | Primary tumor | | | | | Colon | 15 (54) | 5 (38) | 10 (77) | | Rectum | 13 (46) | 8 (62) | 3 (23) | | Sites of metastases | | | | | Liver | 17 (61) | 7 (54) | 8 (62) | | Lung | 9 (32) | 4 (31) | 4 (31) | | Lymph nodes | 10 (36) | 4 (31) | 5 (38) | | Local | 7 (25) | 4 (31) | 3 (23) | | Other | 5 (18) | 1 (8) | 4 (31) | | No. of involved sites | | | | | 1 | 14 (50) | 8 (62) | 5 (38) | | ≥2 | 14 (50) | 5 (38) | 8 (62) | | Single metastatic sites | | | | | Liver-limited | 8 (29) | 4 (31) | 3 (23) | | Other than liver | 7 (25) | 4 (31) | 2 (15) | | Lung | 4 (14) | 2 (15) | 1 (8) | | Lymph nodes | 1 (4) | 1 (8) | — | | Local | 2 (7) | 1 (8) | 1 (8) | | Multiple metastatic sites | 13 (46) | 5 (38) | 8 (62) | | Liver metastases | | | | | Single | 8 (29) | 5 (38) | 3 (23) | | Multiple | 9 (32) | 2 (15) | 7 (54) | | Previous adjuvant chemotherapy | 6 (21) | 3 (23) | 2 (15) | | FA/5-FU bolus | 3 (11) | 2 (15) | — | | FOLFOX4 | 3 (11) | 1 (8) | 2 (15) | | Previous radiotherapy | 2 (7) | 2 (8) | — | RT + CT (5-FU continuous
infusion) | 2 (7) | 2 (8) | — | | RT + CT (XELOX) | — | — | — |
|
|
WHO: world health organization; CIRS: cumulative illness rating scale.
|
